Injectable: Psoraxine™
Novel injectable psoriasis therapy
Psoriasis
Under-treated (only 1 in 4 US sufferers): affects 3% world’s population (14m US/Europe) Total market size US$2bn (JP Morgan/Goldman Sachs)
Current treatments: limited efficacy, potential side effects
Venezuelan clinical studies
2,770 treated to Ministry of Health standards
Around 1 in 4 achieved complete remission Over 1 in 2 experienced 70-99% disease reduction (PASI score)
Technology access and service agreements
SKP to carry out all development
SKP investing up to US$20 m in Astralis over next year